---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-226123"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2022-08-22T23:59:59+00:00"
generated_at: "2026-06-23T22:10:11.765458+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva completes acquisition of La Jolla Pharmaceutical for $6.23 per share

## Summary
- Tender offer accepted 21,703,224 shares (~87.03% of outstanding) at $6.23 per share, no interest.
- Merger completed on August 22, 2022, with La Jolla surviving as wholly-owned subsidiary.
- All outstanding shares (other than Innoviva-Owned and La Jolla-Owned) converted to $6.23 cash per share.
- Series C-1 Preferred Shares converted to cash equal to 1,724.04 times the Merger Consideration.
- Options with exercise price below $6.23 received cash for spread; options at or above $6.23 cancelled for no consideration.

## SEC filing metadata
- accession: 0001193125-22-226123
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2022-08-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000119312522226123/0001193125-22-226123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000119312522226123/d233621d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-226123
- JSON: https://secwatch.observer/filing/0001193125-22-226123.json
- Plain text: https://secwatch.observer/filing/0001193125-22-226123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.